Haleon PLC closed 10.34% below its 52-week high of £4.18, which the company achieved on March 4th.

Pfizer sold its remaining 7.3% stake in Haleon for $3.1 billion, fully exiting its position in the company. Haleon expects 2025 organic revenue growth of 4% to 6%, with stronger performance in the ...

Berenberg raised the firm’s price target on Haleon (HLN) to 460 GBp from 457 GBp and keeps a Buy rating on the shares.Stay Ahead of the Market: ...

Pfizer PFE has sold off its remaining stake in consumer health company Haleon HLN to institutional investors and Haleon itself for around $3.3 billion. Pfizer sold its 7.3% stake in Haleon ...

Haleon PLC closed 11.52% short of its 52-week high of £4.18, which the company reached on March 4th.